What medications can be used to increase platelet count in adults with thrombocytopenia?

Medications to Increase Platelet Count in Adults with Thrombocytopenia

First-Line Treatment

For newly diagnosed immune thrombocytopenia (ITP) with platelet counts <30 × 10⁹/L, corticosteroids are the standard initial treatment, with prednisone 0.5-2 mg/kg/day being the most established first-line therapy. 1, 2

Corticosteroid Options:

• Prednisone: 0.5-2 mg/kg/day until platelet count reaches 30-50 × 10⁹/L (may take days to weeks). Taper rapidly after response, discontinue by 4 weeks in non-responders to avoid complications 1

• Dexamethasone: 40 mg/day for 4 days shows promising results with 50% sustained response in newly diagnosed patients. Can repeat for up to 4 cycles every 14 days, achieving 86% response rate with 74% maintaining response for median 8 months 1

• High-dose methylprednisolone: 30 mg/kg/day for 7 days achieves 95% response rate with faster response time (4.7 days vs 8.4 days for prednisone) 1

Alternative First-Line Agents (when corticosteroids contraindicated):

• Intravenous Immunoglobulin (IVIg): 1 g/kg as single dose (can repeat if needed). Achieves response in up to 80% of patients within 24 hours. Use when rapid platelet increase required 2, 1

• IV Anti-D: 50-75 μg/kg for Rh(D)-positive, non-splenectomized patients. Response rate similar to IVIg, typically within 4-5 days. Caution: Risk of severe intravascular hemolysis, DIC, and renal failure—use with extreme caution 1

Second-Line Treatment (Failed Corticosteroids)

Splenectomy remains the recommended second-line treatment for patients who fail corticosteroid therapy 2. However, delay for at least 12 months unless severe bleeding occurs 2.

Medical Second-Line Options:

Thrombopoietin Receptor Agonists (TPO-RAs) are recommended for patients at bleeding risk who relapse after splenectomy or have contraindications to splenectomy 2:

• Romiplostim: Subcutaneous injection. Achieves 83% overall response rate vs 7% placebo. 50% of patients reach platelet count >50 × 10⁹/L within 2-3 weeks 1, 3

• Eltrombopag: Oral. 70% response at 50 mg/day, 81% at 75 mg/day by day 43. 44-62% achieve response by day 8 1

• Avatrombopag: Oral. Network meta-analysis suggests highest efficacy with most favorable benefit-acceptability balance 4, 3

Ranking by efficacy: Avatrombopag > Romiplostim > Eltrombopag > Rituximab based on network meta-analysis 4, 3

Other Second-Line Agents (Lower Priority):

• Rituximab: May be considered for bleeding risk after failed first-line therapy, though produces lowest overall and early response rates 2, 3

• Azathioprine: 1-2 mg/kg/day (max 150 mg). Response in up to two-thirds of patients, but requires 3-6 months 1

• Cyclosporine: 5 mg/kg/day for 6 days, then 2.5-3 mg/kg/day. Response rate 50-80% within 3-4 weeks 1

• Danazol: 200 mg 2-4 times daily. 67% response rate but requires 3-6 months 1

Emergency/Urgent Treatment

For active bleeding or urgent procedures, combine prednisone with IVIg 1. Additional rapid options include:

• High-dose methylprednisolone
• Platelet transfusion (possibly with IVIg)
• Emergency splenectomy in life-threatening situations 1

Treatment Thresholds

• No treatment needed: Platelet count >50 × 10⁹/L without bleeding, comorbidities, or anticoagulation needs 1
• Consider treatment: Platelet count <30 × 10⁹/L even if asymptomatic 2
• Observation acceptable: Platelet count ≥30 × 10⁹/L without bleeding or risk factors 5

Special Considerations

Pregnancy: Use corticosteroids or IVIg only 2

Chronic refractory ITP (failed splenectomy and multiple therapies): TPO-RAs are first choice. Combination chemotherapy, Campath-1H, or HSCT reserved for severe cases with unacceptable quality of life 1

Critical Pitfalls

• Avoid prolonged corticosteroid use beyond 4-6 weeks due to severe adverse effects outweighing benefits 1
• Monitor for corticosteroid complications: hypertension, hyperglycemia, mood changes, infections, osteoporosis 5
• IV Anti-D carries risk of fatal intravascular hemolysis—premedicate with acetaminophen/corticosteroids and monitor closely 1
• TPO-RAs require monitoring for increased bone marrow reticulin, thrombosis, and liver function abnormalities 1
• Early switch to second-line therapy if requiring on-demand corticosteroids after initial treatment—do not continue ineffective corticosteroid therapy 6